DRL introduces halometasone cream in India
Dr Reddy's Laboratories (DRL) has launched Execare, halometasone cream 0.05 percent in India, used in the treatment of acute/chronic steroid responsive dermatoses and vitiligo. According to ORG figures of May 2009, the topical steroid market size is about Rs 120 crore and growing at 14 percent.
It is a potent steroid and is recommended as an alternative to betamethasone dipropionate and mometasone furoate. With this launch, DRL becomes the first company to introduce this molecule in India.
Halometasone monohydrate has anti-inflammatory action with significant safety and tolerability profile. Corticosteroids act by the induction of lipocortins which prevent the formation of prostaglandins and leukotrienes. Both prostaglandins and leukotrienes are mediators which lead to inflammation. Halometasone acts by blocking their production, thus acting as an anti-inflammatory agent.
The company's leading brands in this segment are Mintop, Ebernet, Venusia and Ultravex.